BIOT Stock Overview
Provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Biotage AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 141.30 |
| 52 Week High | SEK 202.20 |
| 52 Week Low | SEK 81.60 |
| Beta | 0.89 |
| 1 Month Change | 56.31% |
| 3 Month Change | 1.87% |
| 1 Year Change | -20.84% |
| 3 Year Change | -24.44% |
| 5 Year Change | 5.68% |
| Change since IPO | 38.53% |
Recent News & Updates
Recent updates
Biotage's (STO:BIOT) Dividend Will Be Increased To SEK1.65
Apr 08
Biotage AB (publ)'s (STO:BIOT) Popularity With Investors Under Threat As Stock Sinks 26%
Mar 05Is Biotage (STO:BIOT) A Risky Investment?
Feb 20
New Product Launches And Focus On High-Growth Areas Will Strengthen Future Prospects
Feb 09 Expansion in manufacturing capacity and new product launches are likely to drive revenue growth and reduce backlog.Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 48%?
Nov 16Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts
Oct 26Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings
Sep 17Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next
Jul 19Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?
Jun 08Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?
May 21Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Apr 28Biotage's (STO:BIOT) Dividend Will Be SEK1.60
Apr 17Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next
Apr 08Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Apr 03Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Mar 04Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)
Feb 22Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%
Feb 21Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 18Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet
Feb 08Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)
Jan 07At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?
Dec 08Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)
Oct 27Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?
Jul 12An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued
Jun 08Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth
May 24Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 05These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely
Mar 12Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?
Feb 21Shareholder Returns
| BIOT | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 0.1% | 0.05% | 4.0% |
| 1Y | -20.8% | 11.7% | -2.8% |
Return vs Industry: BIOT underperformed the Swedish Life Sciences industry which returned 11.7% over the past year.
Return vs Market: BIOT underperformed the Swedish Market which returned -2.8% over the past year.
Price Volatility
| BIOT volatility | |
|---|---|
| BIOT Average Weekly Movement | 18.1% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in SE Market | 13.7% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: BIOT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: BIOT's weekly volatility has increased from 10% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 622 | Frederic Vanderhaegen | www.biotage.com |
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal and supported scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables, systems, and workflows; biomolecule purification solutions, including antibody, plasmid, AAV, and tagged proteins purification; automation systems; and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns.
Biotage AB (publ) Fundamentals Summary
| BIOT fundamental statistics | |
|---|---|
| Market cap | SEK 11.31b |
| Earnings (TTM) | SEK 255.00m |
| Revenue (TTM) | SEK 1.96b |
44.4x
P/E Ratio5.8x
P/S RatioIs BIOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOT income statement (TTM) | |
|---|---|
| Revenue | SEK 1.96b |
| Cost of Revenue | SEK 733.00m |
| Gross Profit | SEK 1.23b |
| Other Expenses | SEK 973.00m |
| Earnings | SEK 255.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 16, 2025
| Earnings per share (EPS) | 3.19 |
| Gross Margin | 62.62% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 3.9% |
How did BIOT perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield52%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 01:33 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotage AB (publ) is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Odysseas Manesiotis | Berenberg |
| Marcus Bellander | Carnegie Investment Bank AB |